Innate Pharma Reports Share Capital and Voting Rights as of April 9, 2026

Innate Pharma SA ( (FR:IPH) ) has issued an update.

On April 13, 2026, Innate Pharma S.A. reported its capital and voting structure as of April 9, 2026, announcing 93,860,680 shares outstanding, comprised mainly of ordinary shares alongside preferred shares from 2016 and 2017. The company detailed 94,484,443 theoretical voting rights and 94,465,868 exercisable voting rights, providing transparency for investors and regulators on threshold calculations and shareholding structure under French market rules.

The most recent analyst rating on (FR:IPH) stock is a Hold with a EUR3.10 price target. To see the full list of analyst forecasts on Innate Pharma SA stock, see the FR:IPH Stock Forecast page.

More about Innate Pharma SA

Innate Pharma S.A. is a global clinical-stage biotechnology company focused on developing immunotherapies for cancer patients. Leveraging antibody engineering and innovative target identification, it is advancing a portfolio of next-generation antibody therapeutics across solid tumors and lymphomas, including partnered programs such as monalizumab with AstraZeneca and collaborations with major biopharmaceutical and academic institutions.

YTD Price Performance: -27.47%

Average Trading Volume: 195,979

Technical Sentiment Signal: Sell

Current Market Cap: €109M

See more data about IPH stock on TipRanks’ Stock Analysis page.